Rituximab linked to increased inflammatory bowel disease risk in multiple sclerosis patients
A study published in JAMA Neurology found that multiple sclerosis patients treated with rituximab have an increased risk of developing inflammatory bowel disease, particularly Crohn's disease, though the absolute risk remains low. The research compared rituximab to other MS treatments.
